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Abstract 1 
 2 
Background: Up to 60% of patients who undergo curative-intent pancreatic ductal 3 
adenocarcinoma (PDAC) resection experience disease recurrence within six months. We 4 
recently published a systematic review of prognostic immunohistochemical biomarkers in 5 
PDAC and shortlisted a panel of those reported with the highest level of evidence, including 6 
p53, p16, Ca-125, S100A4, FOXC1, EGFR, mesothelin, CD24 and UPAR. This study aims to 7 
discover and validate the prognostic significance of a combinatorial panel of tumor biomarkers 8 
in patients with resected PDAC. 9 
 10 
Methods: Patients who underwent PDAC resection were included from a single institution 11 
discovery cohort and a multi-institutional validation cohort. Tumors in the discovery cohort 12 
were stained immunohistochemically for all nine shortlisted biomarkers. Biomarkers 13 
significantly associated with overall survival (OS) were reevaluated as a combinatorial panel 14 
in both discovery and validation cohorts for its prognostic significance.  15 
 16 
Results: 224 and 191 patients were included in the discovery and validation cohorts, 17 
respectively. In both cohorts, S100A4, Ca-125 and mesothelin expression were associated with 18 
shorter OS. In both cohorts, the number of these biomarkers expressed was significantly 19 
associated with OS (discovery cohort 36.8 vs. 26.4 vs 16.3 vs 12.8 months, P<0.001; validation 20 
cohort 25.2 vs 18.3 vs 13.6 vs 11.9 months, P=0.008 for expression of zero, one, two and three 21 
biomarkers, respectively). On multivariable analysis, expression of at least one of three 22 
biomarkers was independently associated with shorter OS.  23 
 24 
4 
 
Conclusion: Combinations of S100A4, Ca-125 and mesothelin expression stratify survival 1 
after resection of localized PDAC. Co-expression of all three biomarkers is associated with 2 
the poorest prognostic outcome.  3 
  4 
5 
 
1. Introduction 1 
 2 
Pancreatic ductal adenocarcinoma (PDAC) is projected to be the second most common cause 3 
of cancer-related death by 2030.[1] There is mounting evidence that PDAC fails to follow the 4 
traditional Halstedian hypothesis of tumor progression from primary tumor to lymph nodes to 5 
distant metastases. Such data include the acquisition of epithelial-to-mesenchymal traits and 6 
vascular invasion of tumor cells in genetic murine models of PDAC even prior to tumor 7 
formation.[2] Furthermore, integrated genomic investigations have determined distinct 8 
molecular PDAC subtypes based on transcriptomic profiling corresponding to clinical 9 
outcomes.[3-5] These experimental data, coupled with the repeated clinical observation that 10 
R0 pancreatic resection is rarely curative even in the absence of nodal metastases, are leading 11 
to increasing acceptance that PDAC is a systemic disease even when detected “early”.[6] Up 12 
to 60% of patients who have curative-intent pancreatic cancer resection will experience 13 
recurrence of disease at six months postoperatively,[7] supporting the notion that the majority 14 
of patients have clinically inapparent micrometastatic disease at the time of resection. This 15 
demonstrates the inadequacy of preoperative imaging modalities and highlights the need to 16 
integrate tumor biology assessment within staging protocols.  17 
 18 
There has recently been a dramatic increase in the number of potential biomarkers for PDAC. 19 
However, except for Ca19-9[8], few have been clinically validated and entered routine 20 
clinical practice. The current authors recently published a systematic review of all reported 21 
PDAC biomarkers available in blood and/or tissue shown to have prognostic utility.[9] One 22 
hundred and fifty-eight studies were included, and 256 biomarkers were identified and ranked 23 
according to the quality of the evidence and reporting in individual studies. Of the highest 24 
scoring biomarkers, nine were shortlisted such that they represented a range of prognostic 25 
6 
 
outcome parameters and Gene Ontology (GO) processes of oncogenic significance. These 1 
processes include cellular proliferation, cell adhesion, cellular migration, epithelial-to-2 
mesenchymal transition (EMT), and regulation of cell cycle. The nine-biomarker panel 3 
comprised S100A4, Ca-125 (MUC16), mesothelin, CD24, p53, p16, FOXC1, EGFR, and 4 
UPAR (PLAUR). We hypothesized that assessment of these biomarkers as a combinatorial 5 
panel would provide information of prognostic significance. 6 
 7 
In this study, we aimed to: (i) validate the prognostic significance of these nine individual 8 
biomarkers in PDAC, (ii) identify prognostically significant combinations of biomarker 9 
expression in PDAC; and (iii) validate the findings of prognostically significant biomarker 10 
combinations in an external cohort of patients.  11 
 12 
  13 
7 
 
2. Methods 1 
2.1 Study design and selection criteria 2 
This was a cohort study of prospectively collected data and tissue. Separate discovery and 3 
validation cohorts were obtained for analysis. The discovery cohort comprised consecutive 4 
patients who underwent upfront resection of histopathologically proven PDAC at a tertiary 5 
level Australian institution between 1996 and 2016. The validation cohort comprised patients 6 
with histopathologically proven PDAC from whom upfront resected tumor tissue was 7 
collected from 1992-2010 as part of the multi-institutional Australian Pancreatic Genome 8 
Initiative (APGI). Patients from the discovery cohort contained in the validation cohort were 9 
excluded from the latter. Patients with 90-day mortality were excluded from analysis. Ethical 10 
approval was obtained for this project from the Northern Sydney Local Health District 11 
Human Research Ethics Council (ref: HREC/16/HAWKE/105).  12 
 13 
2.2 Patient treatment 14 
All patients underwent standard pancreatic resection (pancreatoduodenectomy, distal 15 
pancreatectomy and splenectomy, or total pancreatectomy). Patients were routinely offered 16 
adjuvant therapy six to eight weeks after surgery. As previously reported, in the period from 17 
2010 to 2016, the rate of commencement of adjuvant chemotherapy in our unit for upfront 18 
resectable patients with PDAC was 84%, of whom 94% received gemcitabine alone and 5% 19 
received gemcitabine plus capecitabine (eight cycles).[10] In the validation cohort, 20 
information regarding adjuvant chemotherapy was available for 181 patients. Fifty-six 21 
(30.9%) patients in the validation cohort received adjuvant chemotherapy. 22 
  23 
 24 
 25 
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2.3 Immunohistochemistry 1 
Tissue microarrays (TMAs) of archived formalin-fixed paraffin embedded (FFPE) PDAC 2 
specimens were formed using 1mm tissue cores of tumor taken from each patient in replicates 3 
of two to six and re-embedded in paraffin. 4µm-thick sections were taken from each TMA 4 
block. Missing cores, or cores where no PDAC tumor could be identified were excluded from 5 
the analysis.  TMA sections were deparaffinized in xylene, rehydrated in graded ethanol 6 
solutions, and quenched in 0.3% hydrogen peroxide. The biomarkers analyzed were: 7 
S100A4, Ca-125 (MUC16), mesothelin, CD24, p53, p16, FOXC1, EGFR, and UPAR 8 
(PLAUR). Secondary antibody incubation was performed (EnVision mouse/rabbit kit; 9 
DAKO, Glostrup, Denmark), followed by chromogen, then hematoxylin counterstain. Details 10 
regarding staining methodology are summarized in Supplementary Table 1.  11 
 12 
Immunolabelling of all antibodies was scored by a surgical pathologist (JT) who was blinded 13 
to all clinical data. With the exception of p53 and S100A4, immunolabelling for all 14 
antibodies was determined as either positive or negative according to the intensity of staining 15 
and the percentage of PDAC tumor cells stained (Figure 1). p53 immunolabelling was 16 
defined as either normal or abnormal, where abnormal staining was defined as either a 17 
complete absence of staining or a diffusely strong pattern of staining. Normal p53 staining 18 
was defined as a scattered patchy pattern of staining as previously described.[11] S100A4 19 
immunostaining was defined as negative, weakly positive, or strongly positive according to 20 
the staining intensity and percentage of PDAC tumor cells stained.  21 
 22 
2.4 Biomarker Combinations 23 
Individual biomarkers significantly associated with shorter overall survival in the discovery 24 
cohort were subsequently evaluated for their capacity to stratify overall survival when 25 
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assessed in combination. These prognostically significant individual biomarkers and their 1 
combinations were re-evaluated in the validation cohort.  2 
 3 
2.5 Clinicopathological data 4 
Clinicopathological data including demographic information, tumor stage, tumor grade, 5 
perineural invasion, lymphovascular invasion, and survival data, were retrieved from a 6 
prospectively maintained database. The survival period was defined as the number of months 7 
from the date of surgery to the date of death. 8 
  9 
2.6 Data analysis 10 
The significance of associations between categorical data were evaluated using Fisher’s exact 11 
test. Univariable survival analyses were performed using Kaplan-Meier method with log-rank 12 
comparison or Cox proportional hazards regression analysis. Clinicopathological factors 13 
found on univariable analysis to be significantly associated with survival in the discovery 14 
cohort were reevaluated in the validation cohort. Variables associated with overall survival 15 
on univariable analysis (P < 0.1) in both discovery and validation cohorts were included in a 16 
multivariable Cox proportional hazards regression model to identify factors independently 17 
associated with overall survival. P values < 0.05 were accepted as statistically significant. All 18 
statistical analyses were performed using SPSS for Windows v25 (IBM, Armonk, NY, USA). 19 
 20 
Where the number of patients analysed did not equate to the number of patients in the entire 21 
cohort, the denominator has been noted in the tables.  22 
 23 
 24 
 25 
26 
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3. Results 1 
3.1 Baseline characteristics 2 
Baseline characteristics are detailed in Table 1. Two hundred and twenty-four patients in the 3 
discovery cohort and 191 patients in the validation cohort met inclusion criteria.  4 
 5 
3.2 Prognostic significance of routine pathological characteristics 6 
A summary of the prognostic significance of key pathological characteristics is detailed in 7 
Table 2. Factors noted to be significantly associated with poor prognosis in both discovery 8 
and validation cohorts included: lymph node positivity, lymphovascular invasion, and 9 
perineural invasion. High tumor grade was significantly associated with poor prognosis in the 10 
discovery but not the validation cohort.  11 
  12 
3.3 Prognostic significance of immunohistochemically evaluated biomarkers 13 
The prognostic significance of individual biomarkers is detailed in Table 2. In the discovery 14 
cohort, on univariable analysis, biomarkers significantly associated with poorer survival in 15 
both discovery and validation cohorts were S100A4, Ca-125, and mesothelin. These three 16 
biomarkers were subsequently evaluated as part of a combinatorial panel. 17 
 18 
3.4 Prognostic significance of combinations of S100A4, Ca-125 and mesothelin 19 
According to the expression pattern of the three biomarkers within each tumor, patients were 20 
categorised as “triple negative”, “single positive”, “double positive”, or “triple positive”. A 21 
“triple negative” category corresponded to failure of tumor expression of all three 22 
biomarkers. A tumor was “single positive”, “double positive”, and “triple positive” where 23 
there was expression of one, two, and three of these biomarkers, respectively.  24 
 25 
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The pattern of biomarker expression across the cohorts is illustrated in Supplementary Table 1 
2. Combinations of S100A4 (strong positivity), Ca-125 and mesothelin expression were 2 
evaluated for their association with overall survival. In both discovery and validation cohorts, 3 
there was an incremental increase in hazard ratio and decrease in 2-year survival with the 4 
expression of each additional biomarker (Figure 2).  Overall survival was significantly 5 
different across all four biomarker combinations (discovery cohort, P < 0.001; validation 6 
cohort, P = 0.008). The triple positive group was associated with the shortest median overall 7 
survival in both cohorts (discovery 12.8 months, validation 11.9 months), whereas the triple 8 
negative group was associated with the longest median overall survival (discovery 36.8 9 
months, validation 25.2 months).  10 
 11 
The expression of at least one of three biomarkers was a significant predictor of overall 12 
survival on multivariable analysis in both the discovery cohort (P=0.020) and the validation 13 
cohort (P=0.014) (Table 3).  14 
 15 
3.5 Correlation of PDAC histological phenotype and biomarker combinations 16 
Histological subtype data were available for the discovery cohort, but not in the validation 17 
cohort. Six patients in this cohort demonstrated features of the rare adenosquamous 18 
histological phenotype of PDAC as defined by morphology. All six of these patients 19 
demonstrated at least a double positive combination of biomarker expression. (P=0.0031, 20 
Fisher’s test).  21 
  22 
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4. Discussion 1 
In this study, we demonstrated for the first time in a discovery and validation cohort that a 2 
panel of three biomarkers (S100A4, CA-125 and mesothelin) is able to stratify patients into 3 
four survival groups after resection of PDAC.  4 
 5 
The ability of this biomarker panel to stratify oncological outcome is maintained despite 6 
significant differences in baseline characteristics between the discovery and validation 7 
cohorts. This strengthens the validity of these findings as they remain applicable to a range of 8 
real-world clinical contexts where there is likely to be significant institutional variation in 9 
patient characteristics, receipt of adjuvant chemotherapy, and overall survival outcomes. In 10 
the present study, the differences in baseline characteristics reflect nationwide referral 11 
patterns, where the discovery cohort comprises patients with more complex tumors who have 12 
been referred to a high-volume tertiary institution from other surgeons. In addition, there is a 13 
more aggressive approach to adjuvant chemotherapy in the discovery cohort.  14 
 15 
In the last decade, there have been significant efforts to profile the genomic landscape of 16 
PDAC. As a result, gene expression data from 456 PDAC tumors revealed that PDAC 17 
comprises four major subtypes, each with a unique transcriptomic signature: (i) squamous; 18 
(ii) pancreatic progenitor; (iii) immunogenic; and (iv) aberrantly differentiated endocrine 19 
exocrine (ADEX).[5] The squamous subtype in particular was associated with the shortest 20 
median overall survival of 13.3 months after pancreatic resection. This subtype was 21 
characterized by upregulation of gene programs including those associated with TP63ΔN 22 
transcriptional targets (responsible for EMT) and Wnt signaling pathways.[2] With such a 23 
short postoperative survival interval, patients exhibiting the squamous subtype of PDAC 24 
probably do not derive significant oncological benefit from surgical resection, whilst 25 
13 
 
enduring the significant postoperative recovery period and reduction in quality of life 1 
associated with pancreatic resection.[12]  2 
 3 
S100A4, Ca-125 and mesothelin are each significantly associated with key biological 4 
processes that characterize the squamous PDAC subtype, which may explain their association 5 
with poorer prognosis in the present study. S100A4 is one of a family of S100 calcium-6 
binding proteins coded on chromosome 1q21, implicated particularly in EMT[13]. Ca-125 7 
expression is also closely linked with Wnt signaling via promotion of β-catenin gene 8 
expression and decrease in cytoplasmic β-catenin degradation.[14] Overexpression of 9 
mesothelin has been demonstrated to promote EMT and stemness by upregulating markers 10 
such as aldehyde dehydrogenase (ALDH), SNAIL, SLUG and TWIST, and downregulating 11 
E-cadherin, caveolin, microphthalmia-associated transcription factor (MITF) and OCLN.[15] 12 
Co-expression of Ca-125 and mesothelin has previously been demonstrated to be associated 13 
with poor survival outcomes in PDAC patients and has been demonstrated to be associated 14 
with worse survival than the expression of either protein alone.[16] Ca-125 and mesothelin 15 
undergo N-glycosylation dependent binding to each other, leading to upregulation of matrix-16 
metalloprotease 7 (MMP-7) and subsequent increase in metastatic potential.[17] 17 
 18 
These data lead to the hypothesis that co-expression of S100A4, Ca-125 and mesothelin is 19 
significantly associated with aggressive tumor biology and potentially the squamous PDAC 20 
subtype – thereby reducing the number of genes required to stratify PDAC patients in future 21 
studies. In the present study, this association was supported by the finding that all PDAC 22 
tumors with the aggressive adenosquamous phenotype expressed at least two of the three 23 
biomarkers. The histological adenosquamous phenotype has previously been demonstrated to 24 
be significantly associated with the squamous PDAC subtype based on gene expression 25 
14 
 
data.[5] This association between biomarker expression and the transcriptomic signature 1 
remains to be evaluated and confirmed in future integrated studies of gene and protein 2 
expression.  3 
 4 
Whilst it is possible to preoperatively analyze tumor subtype at the level of gene expression, 5 
significant financial and logistic barriers prevent this from being routinely applicable to all 6 
patients with resectable PDAC. The difficulties associated with this approach were 7 
highlighted by the IMPaCT trial, which suffered significant participant dropout rate due to 8 
multiple logistic barriers resulting in an inability to return genetic analysis data to 25% of 9 
participants in a timely fashion.[18] Therefore, a more economically viable and practical 10 
solution to profiling tumor biology continues to be required, preferably requiring no 11 
additional infrastructure and utilizing methodologies already employed in the clinical setting, 12 
such as immunohistochemistry.  13 
 14 
The validation of the prognostic utility of these biomarker combinations on 1mm tissue cores 15 
in the present study suggests it may have clinical utility on similarly sized core biopsy 16 
specimens obtained via endoscopic ultrasound (EUS). This should be the subject of future 17 
prospective studies, and may lead to improved pre-operative prognostication of the patient 18 
with PDAC, where reference to such biomarker combinations would allow the clinician to 19 
accurately stratify the risk of early postoperative recurrence and serve as an additional tool in 20 
providing informed consent to patients. Whether patients with triple positive biomarker 21 
expression, for example, may be better treated with an extended course of neo-adjuvant 22 
chemo/chemoradiotherapy instead of earlier resection should also be investigated in future 23 
studies.  24 
 25 
15 
 
In future, the three biomarkers investigated here may demonstrate even greater clinical utility 1 
as they each represent potential therapeutic targets. Anti-S100A4 antibodies have been 2 
demonstrated in vitro to have capacity to abolish tumor growth and angiogenesis in 3 
pancreatic cancer cell lines,[19] but no trials exist yet for the evaluation of S100A4 inhibition 4 
in humans. Novel immunoadhesins to disrupt the interaction between CA-125 and mesothelin 5 
have also demonstrated cytotoxicity against Ca-125-expressing cancer cells in vitro.[20] 6 
Several mesothelin-targeted immunotherapeutic strategies for PDAC have been evaluated in 7 
phase I/II clinical trials including tumor vaccines[21], adoptive CAR T-cell therapy 8 
(NCT01583686 and NCT02159716) and antibody drug conjugates (e.g. anetumab ravtansine 9 
- NCT 03102320, NCT01439152 and NCT02485119).  10 
 11 
Due to the method by which biomarkers were chosen for evaluation in the present study, 12 
which was based on those identified from a previously published systematic review,[9] the 13 
present study has focused on prognostic biomarkers expressed by tumor cells, and has not 14 
considered those expressed by stromal elements. Given the mounting evidence for the role of 15 
stromal elements such as pancreatic stellate cells[23, 24] in the progression of PDAC, 16 
biomarkers related to these factors should also be the subject of future studies.  17 
 18 
There are some limitations in the present study. Whilst the biomarker panel was able to 19 
stratify survival outcomes after PDAC resection in both discovery and validation cohorts, the 20 
absolute values for survival duration should be interpreted with caution as the rates of receipt 21 
of adjuvant chemotherapy and overall survival durations differed significantly between the 22 
two cohorts. In addition, most patients in this study received single-agent gemcitabine, which 23 
is no longer standard of care. The prognostic utility of these biomarkers should therefore be 24 
further evaluated in the setting of modern adjuvant chemotherapeutic combinations. With 25 
16 
 
increasing support for the use of routine neoadjuvant therapy for upfront resectable 1 
PDAC[22], changes in biomarker expression also need to be investigated in future studies in 2 
patients after neoadjuvant chemotherapy. Also, the multivariable analysis in the present study 3 
demonstrating the independent association of the biomarker panel to overall survival is 4 
limited by the absence of margin status in the validation cohort, which has led to its exclusion 5 
from the Cox regression model. The model nevertheless demonstrates a significant 6 
association between the biomarker panel and overall survival independent of the other 7 
prognostically significant covariates listed.  8 
  9 
17 
 
5. Conclusion 1 
S100A4, Ca-125 and mesothelin are prognostically significant biomarkers in pancreatic 2 
cancer. Combinations of these three biomarkers stratify survival after resection of localized 3 
pancreatic cancer. Patients co-expressing all three biomarkers appear to gain minimal 4 
oncological benefit from pancreatic resection.  5 
  6 
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Figure Legends 1 
 2 
Figure 1 – Representative images of positive and negative staining of 3 
immunohistochemically detected biomarkers in tissue microarrays. Original 4 
magnification 10x. A and B, Ca-125 negative and positive (cytoplasmic/membranous) 5 
staining. C and D, CD24 negative and positive staining (cytoplasmic). E and F, EGFR 6 
negative and positive (cytoplasmic/membranous) staining. G and H, FOXC1 negative and 7 
positive (nuclear/cytoplasmic) staining. I and J, mesothelin negative and positive 8 
(cytoplasmic/membranous) staining. K and L, p16 negative and positive 9 
(nuclear/cytoplasmic) staining. M and N, UPAR negative and positive 10 
(cytoplasmic/membranous) staining. O, normal focal scattered pattern of p53 (nuclear) 11 
expression. P, abnormal negative staining for p53 consistent with null mutation. Q, abnormal 12 
diffuse positive staining for p53 consistent with missense mutation. R, S100A4 negative 13 
staining with normal staining of stromal and immune cells. S and T, S100A4 positive and 14 
strong positive (nuclear/cytoplasmic) staining.  15 
 16 
 17 
Figure 2 – Cox Proportional Hazards Survival Curve of the prognostic effect of S100A4, 18 
Ca-125 and Mesothelin combinations. A, Discovery cohort (n=203). B, Validation cohort 19 
(n=169).  20 
  21 
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Table 1 – Baseline clinicopathological characteristics 1 
 2 
Variable Discovery Cohort 
(n=224) 
Number of patients 
(%) 
Median (range) 
Validation Cohort 
(n=191) 
Number of patients 
(%) 
Median (range) 
P-value 
Age, years 69 (34-87) 66 (26-84) 0.002 
Gender, male 98 (43.8) 109 (57.1) 0.008 
Follow-up, months 22 (3-184) 17 (3-229) 0.341 
Overall survival, months 25.3 18.5 0.113 
Adjuvant chemotherapy 116/127 (91.3) 56/181 (30.9) <0.001 
Tumor size, mm 35 (3-100) 28 (8-90) <0.001 
T-stage (AJCC 7th Edition) 
- 1-2 
- 3-4 
 
15 (6.7) 
209 (93.3) 
 
26 (13.6) 
164 (85.9) 
0.014 
Lymph node metastases 
- Negative 
- Positive 
 
81 (36.2) 
143 (63.8) 
 
59 (30.9) 
126 (66.0) 
0.403 
Tumor grade 
- Low 
- High 
 
156 (69.6) 
66 (29.5) 
 
133 (69.6) 
57 (29.8) 
>0.999 
LVI, present 116 (51.8) 77 (40.3) 0.806 
PNI, present 150 (67.0) 142 (74.3) 0.014 
R1 resection (margin 
≤1mm) 
139/215 (64.7) - - 
 3 
LVI, lymphovascular invasion; PNI, perineural invasion.   4 
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Table 2 – Prognostic significance of clinico-pathological variables on overall survival in 1 
discovery and validation cohorts (univariable analysis) 2 
 Discovery Cohort Validation Cohort 
Variable No. of 
patients 
(%) 
Hazard Ratio 
(95%CI) 
P value No. of 
patients 
(%) 
Hazard Ratio 
(95%CI) 
P value 
T-stage 3-4 209/224 
(93.3) 
1.934 
(0.982-3.809) 
0.056 164/190 
(86.3) 
1.450 
(0.939-2.240) 
0.093 
Lymph node 
positivity 
143/224 
(63.8) 
1.471 
(1.056-2.051) 
0.023* 126/185 
(68.1) 
1.597 
(1.142-2.235) 
0.006* 
Tumor grade, 
high 
66/224 
(29.5) 
1.663 
(1.198-2.309) 
0.002* 57/190 
(30.0) 
1.038 
(0.749-1.436) 
0.824 
LVI, present 116/224 
(51.8) 
2.149 
(1.475-3.130) 
<0.001* 77/118 
(65.2) 
1.642 
(1.090-2.472) 
0.018* 
PNI, present 150/224 
(67.0) 
1.507 
(1.020-2.225) 
0.039* 142/167 
(85.0) 
1.628 
(1.013-2.617) 
0.044* 
R1 resection  139/215 
(64.7) 
1.614 
(1.147-2.270) 
0.006* - - - 
≥ 1 of 3 
biomarkers 
positive** 
144/203 
(70.9) 
1.904 
(1.289-2.812) 
0.001* 98/169 
(58.0) 
1.666 (1.202-
2.308) 
0.002* 
S100A4, positive 151/209 
(72.2) 
1.683  
(1.166-2.430) 
0.005* 125/178 
(70.2) 
1.478 
(1.053-2.074) 
0.024* 
S100A4, 
strongly positive 
84/209 
(40.2) 
1.673 
(1.211-2.312) 
0.002* 57/178 
(32.0) 
1.323 
(0.952-1.839) 
0.095 
Ca-125, positive 132/214 
(61.7) 
1.932 
(1.370-2.723) 
<0.001* 77/177 
(43.5) 
1.900 
(1.374-2.628) 
<0.001* 
Mesothelin, 
positive 
37/215 
(17.2) 
1.867 
(1.255-2.778) 
0.002* 28/174 
(16.1) 
1.641 
(1.081-2.490) 
0.020* 
EGFR, positive 11/214 
(5.1) 
1.960 
(0.993-3.869) 
0.052 - - - 
p53, abnormal 66/216 
(30.6) 
1.195 
(0.845-1.691) 
0.314 - - - 
p16, negative 146/213 
(68.5) 
1.075 
(0.768-1.505) 
0.673 - - - 
CD24, positive 17/216 
(7.9) 
1.345 
(0.775-2.334) 
0.292 - - - 
FOXC1, positive 56/212 
(26.4) 
1.224 
(0.856-1.751) 
0.269 - - - 
UPAR, positive 103/213 
(48.4) 
1.117 
(0.814-1.532) 
0.493 - - - 
 3 
LVI, lymphovascular invasion. PNI, perineural invasion.  4 
*denotes P-value <0.05 **Biomarker panel includes S100A4, Ca-125, Mesothelin.  5 
  6 
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Table 3 – Multivariable Cox proportional hazards analysis of the prognostic 1 
significance of pathological factors and biomarker combination on overall survival.  2 
 3 
Variable Discovery Cohort 
(n=161) 
Validation Cohort 
(n=90) 
HR (95%CI) P value HR (95%CI) P value 
T-stage 3-4 1.429 
(0.604-3.381) 
0.417 1.152 
(0.634-2.092) 
0.642 
Node positive 1.817 
(1.180-2.798) 
0.007* 1.477 
(0.910-2.396) 
0.114 
LVI, present 1.903 
(1.229-2.945) 
0.004* 1.616 
(0.932-2.801) 
0.088 
PNI, present 1.118 
(0.707-1.769) 
0.633 1.098 
(0.572-2.105) 
0.779 
≥ 1 out of 3 
biomarkers 
positive  
1.729 
(1.088-2.747) 
0.020* 1.750 
(1.119-2.734) 
0.014* 
 4 
LVI, lymphovascular invasion. PNI, perineural invasion.  5 
* denotes P-value <0.056 
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Supplementary Table 1 – Immunohistochemical antibody details 
 
Antibody Company Clone Mouse/Rabbit HIER HIER 
Duration 
Dilution Chromogen Staining 
Method 
UPAR Dako* R4 Mouse pH 6 15mins 1:45 INR Manual 
CD24 ThermoFisher** SN3b Mouse pH 9  20mins 1:100 INR Manual 
S100A4 Dako* A5114 Rabbit pH 6 20mins 1:1000 INR Manual 
FOXC1 Atlas++ HPA040670 Rabbit pH 9  20mins 1:100 INR Manual 
Mesothelin Novocastra*** 5B2 Mouse pH 6 20mins 1:20 DAB Autostainer 
EGFR Dako* H11 Mouse pH 6 20mins 1:100 DAB Autostainer 
p16 Santa-Cruz+ JC8 Mouse pH 6 20mins 1:200 DAB Autostainer 
p53 Dako* DO7 Mouse pH 6 20mins 1:50 DAB Autostainer 
Ca-125 Dako* M11 Mouse pH 9  20mins 1:100 INR Manual 
 
HIER, Heat induced epitope retrieval. INR, ImmPact NovaRED (Vector Laboratories, Burlingame, CA, USA). DAB, 3,3’Diaminobenzidine. 
*Dako/Agilent (Santa Clara, CA, USA). **Thermofisher (Waltham, MA, USA). +Santa-Cruz (Dallas, TX, USA). ++Atlas (Bromma, Sweden). 
***Novocastra Laboratories (Newcastle Upon Tyne, UK).
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Supplementary Table 2 – S100A4, Ca-125 and mesothelin biomarker combinations in 
discovery and validation cohorts 
 Category All 
Negative 
S C M S + C S + M C + M S+C+M 
D
is
co
v
er
y
 
(n
=
2
0
3
) 
Triple 
Negative 
(n=59) 
59        
Single 
Positive 
(n=65) 
 17 46 2     
Double 
Positive 
(n=58) 
    44 1 13  
Triple 
Positive 
(n=21) 
       21 
V
a
li
d
a
ti
o
n
  
(n
=
1
6
9
) 
Triple 
Negative 
(n=40) 
40        
Single 
Positive 
(n=59) 
 53 6 0     
Double 
Positive 
(n=44) 
    42 0 2 
 
Triple 
Positive 
(n=26) 
       26 
 
S, S100A4; C, Ca-125; M, mesothelin.  
 
